Comparative Pharmacology
Head-to-head clinical analysis: ACEON versus ALTACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEON versus ALTACE.
ACEON vs ALTACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACEON (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased vasopressor activity, reduced aldosterone secretion, and lower peripheral vascular resistance, leading to antihypertensive effects.
Angiotensin-converting enzyme inhibitor; inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion.
Initial: 4 mg orally once daily; titrate to 8-32 mg daily in 1-2 divided doses. Typical maintenance: 8-16 mg daily.
2.5-5 mg orally once daily initially, titrated to 10-20 mg once daily; maximum 20 mg/day
None Documented
None Documented
Perindoprilat: terminal half-life ~30 hours (up to 120 hours in elderly or heart failure due to prolonged terminal phase from slow dissociation from ACE binding); perindopril: ~1.5 hours.
Ramiprilat: 13–17 hours (prolonged in renal impairment, up to 50 hours in severe renal insufficiency; multiple doses: 45–60 hours effective half-life due to tissue binding)
Renal: approximately 30% as perindopril and 20% as perindoprilat; fecal: approximately 50% as metabolites.
Renal: 60% (30% as ramiprilat, 30% as metabolites); Fecal: 40% (unabsorbed drug and biliary metabolites)
Category C
Category C
ACE Inhibitor
ACE Inhibitor